Look before you SPRINT: look at the data and look at the consequences

The SPRINT trial’s serious problems in internal and external validity require great caution in implementing the new US blood pressure guideline.

Excipients: not so inert? When the excipient plays the role of an active substance, as exemplified by systemic lupus

The choice of excipients is central in the drug development process. A bad choice of excipient can modify or masking the effect of the active substance. Some so-called excipients display bioactivity themselves, which can lead to unwanted effects in patients.

Supplementum 230: Swiss Oncology & Hematology Congress (SOHC)